Pan Feng, Male, born in November 1979, an associate researcher. His researches mainly focus on research and development of sustained/controlled release products with biodegradable matrix. In 2001, he graduated from Pharmacy specialty of Fudan University acquiring the Bachelor's Degree, then worked in Pharmaceutical Preparation Section of International Peace Maternity & Child Health Hospital of China welfare institute (IPMCH) from 2001 to 2002. He worked on R & D of new sustained/controlled release dosage forms in Pharmaceutical Preparation Section of Shanghai Institute of Pharmaceutical Industry (SIPI) from 2002 to 2010, where he finally obtained his Master's Degree in 2007. Furthermore, from 2010 to 2013, he was occupied in new drug dosage form research and development in the National Pharmaceutical Engineering Research Center (NPERC) of Pharmaceutical Preparation. From 2013 up to now, he works in Drug Development Section of the Shanghai Institute of Planned Parenthood Research (SIPPR) to develop biodegradable long-acting drug delivery systems by virtue of some technologies such as microspheres and implants, etc.. With rich experience in R & D of biodegradable sustained/controlled release drug dosage forms, he used to preside over or participate more than 10 research subjects, including the National “12th Five Year Plan” program, international cooperation projects, key research projects of Science and Technology Commission of Shanghai Municipality and enterprise cooperation projects, etc.. At present, he mainly takes part in a special sub-topic of the study on reproductive health and major birth defect prevention and control of the National “13th Five Year Plan”, named as Research and Development of New Contraceptive Medicine with A Therapeutic Effect of Biodegradable Long-acting Controlled-release New Dosage Forms, and a subject referred to as Development of 6 Months Release Levonorgestrel-loaded PLA/ PLGA Microsphere Injection funded by FHI. In total, he has published 12 academic papers and obtained 8 Chinese patents and 1 authorized patent for utility models.